Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first
From BioCentury This Week · · 30 min
This plays from the publisher's own server. We do not host a copy.
Description
AbbVie's $10.9 billion deal to acquire (https://www.biocentury.com/article/659848) Apogee will expand its immunology pipeline by delivering assets for atopic dermatitis and asthma. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the takeout and the assets AbbVie gains. The analysts then discuss moves by FDA to reverse controversial setbacks that occurred under the agency’s former leadership and assess Acting CDER Director Michael Davis’ memo (https://www.biocentury.com/article/659804)outlining how his predecessor repeatedly overruled career staff to quash a drug approval. The analysts also discuss continuing signs of political involvement (https://www.biocentury.com/article/659836) at FDA. Finally, they discuss China NMPA’s first-ever approval of a CAR T for solid tumors (https://www.biocentury.com/article/659859), satricabtagene autoleucel (satri-cel) from Carsgen.
View full story: https://www.biocentury.com/article/659864
#BiotechMA #Immunology #FDA #CART #ChinaBiotech
00:59 - AbbVie Buys Apogee 05:20 - uniQure U-turn 09:02 - FDA Reversals 12:32 - Tzield Memo 20:53 - Solid Tumor CAR T Approval
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)